Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
Lucid Diagnostics (Nasdaq: LUCD), a company focused on cancer prevention medical diagnostics, has launched a newly redesigned corporate website (www.luciddx.com) as announced on July 11, 2024. This improved platform aims to provide an enhanced user experience for patients, healthcare professionals, investors, and other stakeholders. According to Jenna Mowatt, Vice President of Marketing and Communications, the website is designed to reflect the company's mission to prevent esophageal cancer and showcase its innovative technologies through a modern design and comprehensive content. Lucid Diagnostics encourages visitors to explore the new website for more information.
Lucid Diagnostics announced positive results from its ESOGUARD BE-1 clinical validation study for EsoGuard, a test for detecting esophageal precancer. The study showed an 87.5% sensitivity and a 98.6% negative predictive value (NPV). The study was conducted across multiple international centers, including major U.S. and European institutions. The results support the upcoming Medicare LCD pre-submission and ongoing commercial payor engagements. The study involving 93 subjects confirmed the test's efficiency and safety, potentially making esophageal cancer screening more accessible and effective.
Lucid Diagnostics announced that its EsoGuard® Esophageal DNA test has been used on the 4,000th firefighter as part of the #CheckYourFoodTube Precancer Testing Event, held by Mass General Brigham physicians and Boston Firefighters Local 718. The event aims to address the elevated risk of esophageal cancer among firefighters. This milestone event is part of Lucid Diagnostics' broader strategy to increase test volumes and highlights the importance of early cancer detection. Firefighters face a 62% higher risk of developing esophageal cancer and a 39% higher risk of dying from it. Estimates from the American Cancer Society suggest 22,370 new cases and 16,130 deaths from esophageal cancer in 2024.
PAVmed (NASDAQ: PAVM) provided a business update and reported financial results for Q1 2024. The company held a webcast on May 14, 2024, to discuss the results. Lucid Diagnostics, a subsidiary, completed a $29.8 million Series B offering, securing key reimbursement milestones. Veris Health signed an MOU with The Ohio State's James Cancer Hospital. Financially, PAVmed reported $1.0 million in EsoGuard revenues, flat quarter-over-quarter but a 124% increase from Q1 2023. Operating expenses were $15.0 million with a GAAP net loss of $22.8 million. Cash reserves stood at $25.5 million as of March 31, 2024.
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, provided a business update and financial results for the first quarter of 2024. The company reported a 10% increase in EsoGuard test volume, a strengthened balance sheet after a $29.8 million Series B Preferred Stock Offering, and a MolDX pre-submission meeting scheduled for July 17, 2024. Lucid also highlighted revenue growth, clinical study outcomes, and market access strategy.
Lucid Diagnostics Inc. announced that the EsophaCap sponge-on-a-string esophageal cell collection device has been subjected to a Class II FDA recall due to serious device failures reported. Lucid's EsoCheck® remains unaffected by the recall and continues to be the gold standard for non-endoscopic cell collection. The recall stemmed from two serious device failures reported in a recent publication of one of the studies using the EsophaCap device. Lucid's EsoCheck® is a modern technology enabling precise, targeted cell collection for esophageal precancer testing, offering unprecedented early precancer detection without causing any serious adverse events.
Lucid Diagnostics Inc. (Nasdaq: LUCD) has successfully closed a Series B-1 Preferred Stock offering, generating $29.8 million in gross proceeds. The offering was led by a long-time institutional investor, providing the company with substantial working capital. As part of this development, Dennis Matheis, a seasoned healthcare industry veteran, has been appointed to the Board of Directors. Matheis currently holds the position of President and CEO at Sentara Health, a prominent not-for-profit integrated health system in the U.S. Lucid aims to leverage this funding to achieve key reimbursement milestones and enhance its operational capabilities.
Lucid Diagnostics, a cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., will hold a business update conference call and webcast on May 13, 2024, at 8:30 AM ET. The call will feature Lucid's CEO providing an operational overview and growth strategy, along with the CFO discussing first-quarter 2024 financial results. Investors can access the webcast on the company's website or join via telephone.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the publication of positive data from a National Cancer Institute-sponsored study on EsoGuard® Esophageal Precancer Testing, showing 89% sensitivity in detecting early precancer. The study strengthens EsoGuard's clinical data and supports efforts for commercial and Medicare coverage.
Lucid Diagnostics, a cancer prevention medical diagnostics company, partners with the Esophageal Cancer Action Network (ECAN) to raise awareness during Esophageal Cancer Awareness Month. The partnership aims to educate about the link between heartburn and esophageal cancer, promoting early detection for prevention. Public service videos are being displayed in Times Square, emphasizing the importance of screening for those at risk.